David Mengel
Has participated in:
-
Wirkmechanismen des MAP-Kinase Inhibitors CNI-1493 auf mikrogliale BV-2 Zellen und primäre Mikroglia
-
Wirkmechanismen des MAP-Kinase Inhibitors CNI-1493 auf mikrogliale BV-2 Zellen und primäre Mikroglia
-
A systematic review of progranulin concentrations in biofluids in over 7,000 people—assessing the pathogenicity of GRN mutations and other influencing factors
-
Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study